A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

NCT05458219 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

470

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced Unresectable or Metastatic Solid Tumors

Interventions

DRUG: IBI343
DRUG: FOLFIRINOX/mFOLFIRINOX
DRUG: mFOLFOX
DRUG: IBI343

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Collaborators

[object Object]
[object Object]